.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Dow
Moodys
Accenture
Baxter
Farmers Insurance
Cerilliant
UBS
Cantor Fitzgerald
Harvard Business School

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,078,381

« Back to Dashboard

Which drugs does patent 7,078,381 protect, and when does it expire?


Patent 7,078,381 protects JANUMET XR, JENTADUETO XR, GLYXAMBI, JANUMET, JANUVIA, JENTADUETO, JUVISYNC, KAZANO, NESINA, OSENI, and TRADJENTA, and is included in eleven NDAs. There have been zero Paragraph IV challenges on Nesina, Kazano, Jentadueto, Tradjenta, Juvisync, Janumet XR, , and .

This patent has twenty-two patent family members in seven countries.

Summary for Patent: 7,078,381

Title:Method of regulating glucose metabolism, and reagents related thereto
Abstract:The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.
Inventor(s): Bachovchin; William W. (Melrose, MA), Plaut; Andrew G. (Lexington, MA), Drucker; Daniel (Toronto, CA)
Assignee: Trustees of Tufts College (Medford, MA)
Application Number:10/794,316
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp DohmeJANUMET XRmetformin hydrochloride; sitagliptin phosphateTABLET, EXTENDED RELEASE;ORAL202270-002Feb 2, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp DohmeJANUMET XRmetformin hydrochloride; sitagliptin phosphateTABLET, EXTENDED RELEASE;ORAL202270-003Feb 2, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Merck Sharp DohmeJANUMET XRmetformin hydrochloride; sitagliptin phosphateTABLET, EXTENDED RELEASE;ORAL202270-001Feb 2, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Boehringer IngelheimJENTADUETO XRlinagliptin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208026-001May 27, 2016RXYesNo► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN► Subscribe
Boehringer IngelheimJENTADUETO XRlinagliptin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208026-002May 27, 2016RXYesYes► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN► Subscribe
Boehringer IngelheimGLYXAMBIempagliflozin; linagliptinTABLET;ORAL206073-001Jan 30, 2015RXYesNo► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN► Subscribe
Boehringer IngelheimGLYXAMBIempagliflozin; linagliptinTABLET;ORAL206073-002Jan 30, 2015RXYesYes► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN► Subscribe
Merck Sharp DohmeJANUMETmetformin hydrochloride; sitagliptin phosphateTABLET;ORAL022044-002Mar 30, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Merck Sharp DohmeJANUMETmetformin hydrochloride; sitagliptin phosphateTABLET;ORAL022044-001Mar 30, 2007RXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp DohmeJANUVIAsitagliptin phosphateTABLET;ORAL021995-001Oct 16, 2006RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,078,381

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,513,190Method of regulating glucose metabolism, and reagents related thereto► Subscribe
6,803,357 Method of regulating glucose metabolism, and reagents related thereto► Subscribe
9,044,424Methods of regulating glucose metabolism, and reagents related thereto► Subscribe
8,318,669Method of regulating glucose metabolism, and reagents related thereto► Subscribe
7,459,428Method of regulating glucose metabolism, and reagents related thereto► Subscribe
7,829,530Method of regulating glucose metabolism, and reagents related thereto► Subscribe
7,157,429Method of regulating glucose metabolism, and reagents related thereto► Subscribe
6,890,898 Method of regulating glucose metabolism, and reagents related thereto► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,078,381

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2003264609► Subscribe
Australia2493599► Subscribe
Australia766219► Subscribe
Canada2319195► Subscribe
Canada2755452► Subscribe
Canada2819705► Subscribe
Germany04029691► Subscribe
European Patent Office1052994► Subscribe
European Patent Office1520582► Subscribe
European Patent Office2433623► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Julphar
Novartis
Cantor Fitzgerald
Cipla
Mallinckrodt
Daiichi Sankyo
Johnson and Johnson
Farmers Insurance
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot